Key facts
- Aquit’s last known valuation is $3.3M (Jun 2023).
- It has raised $1.4M; the latest was Accelerator/Incubator in Dec 2025.
- Notable investors include Hatch Blue, Grid Exponential, Corporación de Fomento de la Producción de Chile, Bright Tide, Marcelo Gabor — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Aquit
- ·The full record, as it builds
Funding rounds
No funding rounds for Aquit are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aquit
Developer of preventive treatment for infections and diseases in fish intended to improve survival rates, growth, and animal welfare by replacing antibiotics. The company is developing products that boost natural immunity in fish, enhancing its defense and survival against bacterial pathogens and diseases, providing aquaculture producers with cost-effective and easy-to-access sustainable solutions, enabling fish cultivators to create sustainable options for aquaculture.
- Sector
- Materials and Resources
- HQ
- Viña del Mar, Chile
- Founded
- 2017
- Employees
- 7
- Website
- aquit.net/
- Ownership
- Privately Held (backing)
Aquit doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aquit shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aquit in its N-PORT filings yet. We sweep new filings monthly.